
Overview
Aditya Halthore, MD, serves as Assistant Professor in the Department of Radiation Oncology and Molecular Radiation Sciences and Director of Safety and Quality at the Johns Hopkins University School of Medicine. Listen to Dr. Halthore's On Target podcast episode to learn more about his work. Dr. Halthore is an expert in proton therapy and specializes in genitourinary and thoracic cancers. His specific interests include prostate, bladder, lung, esophageal, and thymic cancers, and he is committed to developing personalized treatment strategies for every patient. Dr. Halthore was previously recognized as a Howard Hughes Medical Institute (HHMI)/National Institutes of Health (NIH) Scholar and his research interests include grant funded clinical trials focused on the novel utilization of radiation and imaging techniques, such as spatial fractionation (proton GRID) therapy for the treatment of bulky cancers. He is also involved in using dual-energy CT and functional MRI studies that aim to improve functional radiation planning and the assessment of radiation-induced changes. As an educator, Dr. Halthore serves as Course Director for the Johns Hopkins Proton Therapy Certificate Program. He actively participates in student, resident, and fellow lectureship and mentorship across the Johns Hopkins health system. Dr. Halthore participates in several national-level initiatives including as a member of the American Society of Therapeutic Radiation Oncology (ASTRO) Guidelines Subcommittee and as a board member and ASTRO liaison to the Medical Dosimetry Certification Board (MDCB).
Dr. Halthore is rated as a Distinguished provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Prostate Cancer, Small Cell Lung Cancer (SCLC), Marginal Zone Lymphoma (MZL), and Familial Prostate Cancer.
His clinical research consists of co-authoring 22 peer reviewed articles. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 4 articles in the study of Prostate Cancer.
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- HMO
- POS
- PPO
- EPO
- HMO
- PPO
- INSURANCE PLAN
- MEDICARE PDP
- PPO
- HMO
- POS
- PPO
- HMO
- INDEMNITY
- POS
- PPO
- HMO
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE-MEDICAID PLAN
- OTHER MANAGED MEDICAID
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
5255 Loughboro Road Northwest, Washington, DC 20016
300 Mason Lord Drive, Kimmel Cancer Center, Baltimore, MD 21224
5255 Loughboro Road Northwest, Washington, DC 20016
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Sidney Kimmel Comprehensive Cancer Center
Dr. Daniel (Danny) Song is a Professor of Radiation Oncology, with joint appointments in Urology and Oncology. He serves as the Co-director of the Prostate Cancer Multidisciplinary Clinic at the Johns Hopkins Hospital and the Physician Advisor and Director of Faculty Affairs for the Department of Radiation Oncology and Molecular Radiation Sciences. His area of clinical expertise is in the management of genitourinary cancers, including cancers of the prostate, bladder and urinary tract, and testicular cancer. Dr. Song applies his expertise and clinical experience in the utilization of a variety of radiation modalities including external beam radiation, image-guided and intensity-modulated radiation, prostate brachytherapy (seed implants), and stereotactic body radiation therapy. Dr. Song's research interests include the development and refinement of new imaging methods to improve radiation targeting, as well as innovative means of reducing potential side effects of radiation treatment. His research is supported by federal and private research funding programs including two R01 awards from the National Cancer Institute, Department of Defense Prostate Cancer Clinical Trial Award, the American Cancer Society, and the Hopkins-BMS Immuno-Oncology Consortium. He is a reviewer and examiner for the American Board of Radiology, which administers the national board certification examination for radiation oncologists. He has served on the editorial boards of the International Journal of Radiation Oncology, Biology, Physics and The Prostate, and on the scientific review committees for the American Society for Radiation Oncology (ASTRO), American Brachytherapy Society, and the Dept of Defense Prostate Cancer Research Program. He currently serves on the Scientific Planning Committee for the American Brachytherapy Society annual meeting. He has co-authored consensus guidelines on stereotactic body radiation therapy (TG-101) and image-guided robotic brachytherapy (TG-192) produced by the American Association of Physics in Medicine. Dr. Song sees patients at the Johns Hopkins Hospital (downtown Baltimore) as well as Greenspring Station (Timonium) practices. Make A Gift. Dr. Song is rated as a Distinguished provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Muscle Invasive Bladder Cancer, Prostatectomy, and Endoscopy.
Sibley Memorial Hospital
Curtiland Deville, MD, is the Medical Director of the Johns Hopkins Proton Therapy Center, Clinical Director of Radiation Oncology at Sibley Memorial Hospital, co-director of the Kimmel Cancer Center Prostate Multidisciplinary Clinic at Sibley Memorial Hospital and an Associate Professor at the Johns Hopkins University School of Medicine. Dr. Deville is an expert in proton therapy and a leader in several institutional and national clinical trials. He treats genitourinary malignancies, including prostate cancer, and soft tissue sarcomas, and is dedicated to creating individualized treatment plans for each patient. His research interests involve better targeting tumors through proton and photon therapies and reducing radiation to healthy tissues. He analyzes toxicity rates with modern radiation techniques and uses the most advanced technology for his patients’ care. Dr. Deville is also a Senior Editor for Advances in Radiation Oncology, as well as a reviewer for several journals that focus on radiation oncology. He is an expert on physician workforce diversity and widely published in the field. He is the immediate past Chair of the American Society of Radiation Oncology's Committee on Health Equity, Diversity and Inclusion and Chair of the American Society of Clinical Oncology’s Diversity in Oncology Subcommittee. LinkedIn https://www.linkedin.com/in/curtiland-deville-37133136. Dr. Deville is rated as a Distinguished provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Myxoid Liposarcoma, Liposarcoma, and Prostatectomy.
Anatoly Dritschilo is a Radiation Oncologist in Washington, Washington, D.c.. Dr. Dritschilo is rated as a Distinguished provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Medulloblastoma, and Embryonal Tumor with Multilayered Rosettes.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Distinguished
- Prostate CancerDr. Halthore isDistinguished. Learn about Prostate Cancer.
- Advanced
- ALK-Positive Non-Small Cell Lung Cancer
- Breast CancerDr. Halthore isAdvanced. Learn about Breast Cancer.
- Familial Prostate CancerDr. Halthore isAdvanced. Learn about Familial Prostate Cancer.
- Lung AdenocarcinomaDr. Halthore isAdvanced. Learn about Lung Adenocarcinoma.
- Marginal Zone Lymphoma (MZL)Dr. Halthore isAdvanced. Learn about Marginal Zone Lymphoma (MZL).
- Pleuropulmonary BlastomaDr. Halthore isAdvanced. Learn about Pleuropulmonary Blastoma.
- Experienced
- Adult Soft Tissue SarcomaDr. Halthore isExperienced. Learn about Adult Soft Tissue Sarcoma.
- EGFR Positive Lung CancerDr. Halthore isExperienced. Learn about EGFR Positive Lung Cancer.
- Fibrodysplasia Ossificans ProgressivaDr. Halthore isExperienced. Learn about Fibrodysplasia Ossificans Progressiva.
- Large-Cell Lung CarcinomaDr. Halthore isExperienced. Learn about Large-Cell Lung Carcinoma.
- Laryngeal CancerDr. Halthore isExperienced. Learn about Laryngeal Cancer.
- Lung CancerDr. Halthore isExperienced. Learn about Lung Cancer.

